Anika Therapeutics reported $2.52M in EBITDA for its first fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
Abbott ABT:US $ 2840M 589M
Acorda Therapeutics ACOR:US $ -18.97M 8.85M
Adamas Pharmaceuticals ADMS:US -14786000 6.22M
Agenus AGEN:US $ -39.64M 16.34M
Agios Pharmaceuticals AGIO:US $ -88.74M 1.02M
Anika Therapeutics ANIK:US $ 2.52M 5.09M
Arrowhead Research ARWR:US $ -26310000 4.1M
Dicerna Pharmaceuticals DRNA:US $ -28.29M 2.76M
Halozyme Therapeutics HALO:US $ 78.42M 37.32M
Immunogen IMGN:US $ 37.01M 53.22M
Insmed INSM:US $ -79912000 10.78M
Integra Lifesciences IART:US $ 87.12M 16.27M
Johnson & Johnson JNJ:US $ 9474.4M 2992.4M
Karyopharm Therapeutics KPTI:US $ -52138000 15.33M
Ligand Pharmaceuticals LGND:US $ 16.92M 9.78M
Macrogenics MGNX:US $ -48564000 49.33M
Merit Medical Systems MMSI:US $ 26.62M 21.68M
Rigel Pharmaceuticals RIGL:US $ 41.99M 60.62M
Sangamo Biosciences SGMO:US $ -44.43M 2.68M
Stryker SYK:US $ 866M 458M
Surmodics SRDX:US $ 11.39M 9.44M
Veracyte VCYT:US $ -6.05M 3.97M
Xencor XNCR:US $ -14.03M 1.87M